A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Novo Nordisk A S stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 32,131 shares of NVO stock, worth $3.38 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
32,131
Previous 32,805 2.05%
Holding current value
$3.38 Million
Previous $4.68 Million 18.3%
% of portfolio
0.03%
Previous 0.04%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$119.07 - $145.42 $80,253 - $98,013
-674 Reduced 2.05%
32,131 $3.83 Million
Q2 2024

Jul 17, 2024

BUY
$122.71 - $146.91 $1.53 Million - $1.84 Million
12,504 Added 61.59%
32,805 $4.68 Million
Q1 2024

Apr 23, 2024

SELL
$102.11 - $135.92 $13,784 - $18,349
-135 Reduced 0.66%
20,301 $2.61 Million
Q3 2023

Nov 03, 2023

BUY
$90.94 - $199.54 $921,949 - $2.02 Million
10,138 Added 98.45%
20,436 $1.86 Million
Q1 2023

May 02, 2023

SELL
$132.34 - $159.14 $86,153 - $103,600
-651 Reduced 5.95%
10,298 $1.64 Million
Q4 2022

Mar 02, 2023

BUY
$102.55 - $135.33 $10,870 - $14,344
106 Added 0.98%
10,949 $1.48 Million
Q4 2022

Feb 14, 2023

SELL
$102.55 - $135.33 $10,870 - $14,344
-106 Reduced 0.97%
10,843 $1.53 Million
Q4 2021

Feb 14, 2022

SELL
$95.88 - $117.08 $15,340 - $18,732
-160 Reduced 1.44%
10,949 $1.23 Million
Q3 2021

Nov 12, 2021

SELL
$84.42 - $106.62 $77,666 - $98,090
-920 Reduced 7.65%
11,109 $1.07 Million
Q2 2021

Aug 13, 2021

SELL
$67.66 - $84.76 $8,051 - $10,086
-119 Reduced 0.98%
12,029 $1.01 Million
Q1 2021

Apr 14, 2021

SELL
$67.06 - $75.82 $1,810 - $2,047
-27 Reduced 0.22%
12,148 $819,000
Q4 2020

Jan 14, 2021

BUY
$63.89 - $73.8 $17,569 - $20,295
275 Added 2.31%
12,175 $850,000
Q2 2020

Jul 30, 2020

BUY
$58.54 - $67.94 $29,270 - $33,970
500 Added 4.39%
11,900 $779,000
Q1 2020

Apr 15, 2020

SELL
$49.46 - $64.78 $231,967 - $303,818
-4,690 Reduced 29.15%
11,400 $686,000
Q4 2019

Jan 22, 2020

SELL
$49.86 - $58.26 $656,157 - $766,701
-13,160 Reduced 44.99%
16,090 $931,000
Q3 2019

Nov 05, 2019

SELL
$47.54 - $53.43 $331,353 - $372,407
-6,970 Reduced 19.24%
29,250 $1.51 Million
Q2 2019

Aug 09, 2019

SELL
$46.79 - $52.47 $1.42 Million - $1.6 Million
-30,442 Reduced 45.67%
36,220 $1.85 Million
Q1 2019

Apr 08, 2019

SELL
$46.36 - $52.63 $24.5 Million - $27.9 Million
-529,279 Reduced 88.81%
66,662 $3.49 Million
Q4 2018

Feb 13, 2019

SELL
$41.54 - $47.25 $3.02 Million - $3.44 Million
-72,811 Reduced 10.89%
595,941 $27.5 Million
Q3 2018

Oct 31, 2018

SELL
$46.76 - $51.24 $2.68 Million - $2.93 Million
-57,232 Reduced 7.88%
668,752 $31.5 Million
Q2 2018

Aug 07, 2018

SELL
$44.29 - $50.42 $4.28 Million - $4.87 Million
-96,621 Reduced 11.75%
725,984 $33.5 Million
Q1 2018

Apr 20, 2018

SELL
$48.49 - $58.14 $10.7 Million - $12.8 Million
-220,331 Reduced 21.13%
822,605 $40.5 Million
Q4 2017

Feb 08, 2018

SELL
$47.53 - $53.73 $1.7 Million - $1.92 Million
-35,724 Reduced 3.31%
1,042,936 $56 Million
Q3 2017

Oct 27, 2017

SELL
$41.15 - $49.22 $1.74 Million - $2.09 Million
-42,389 Reduced 3.78%
1,078,660 $51.9 Million
Q2 2017

Aug 07, 2017

BUY
N/A
1,121,049
1,121,049 $0

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $238B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Loring Wolcott & Coolidge Fiduciary Advisors LLP Portfolio

Follow Loring Wolcott & Coolidge Fiduciary Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.